Experimental AATD drug trial halted early: what we know
Disease control
Terminated
This early-stage study tested a new drug, KRRO 110, in healthy volunteers and people with Alpha-1 antitrypsin deficiency (AATD), a genetic condition that can damage the lungs and liver. The main goal was to check safety and how the drug moves through the body. The trial was termi…
Phase: PHASE1, PHASE2 • Sponsor: Korro Bio, Inc. • Aim: Disease control
Last updated May 01, 2026 15:58 UTC